TICKERNERD
Menu
ERNAERNAHealthcare · Biotechnology

ERNA Stock Forecast: Ernexa Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$1.97
−6.64% on the day

The 1 Wall Street analysts covering Ernexa Therapeutics, Inc. hold a median 12-month price target of $30 — +1422.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$3.2M
Ticker Nerd rank
39/ 100
Median analyst target
$30
Analysts covering
1
Revenue$0.0
Operating income−$4.1M
Net income−$4.0M
Free cash flow−$4.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.8%
1M
−38.4%
YTD
−93.4%
1Y
−95.6%
From 52W high
−95.8%
From 52W low
+1.5%
$2
$47
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ERNA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Ernexa Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
39/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
97
Accruals
91
Revisions
56
Growth
53
Issuance
45
Momentum
26
Quality
16
Volatility
12
Value
9

Size (97): Smaller than most of the companies we track.

Value (9): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ERNA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ERNA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Jan 26Apr 26Jul 26Oct 26ERNAHigh $30Median $30Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $30Median $30High $30

The green dot is the last close — the median target sits +1422.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 May 2026Brookline CapitalInitiatesBuy$30
14 Dec 2022Morgan StanleyMaintainsEqual-Weight—
12 Dec 2022B of A SecuritiesUpgradeBuy—
14 Nov 2022NeedhamMaintainsBuy—
10 Aug 2022NeedhamMaintainsBuy—
15 July 2022Morgan StanleyMaintainsEqual-Weight—
12 May 2022JP MorganUpgradeOverweight—
11 May 2022NeedhamMaintainsBuy—
2 Mar 2022NeedhamMaintainsBuy—
11 Nov 2021NeedhamMaintainsBuy—
1 Oct 2021NeedhamMaintainsBuy—
16 June 2021Morgan StanleyMaintainsEqual-Weight—
13 May 2021NeedhamMaintainsBuy—
21 Apr 2021JP MorganInitiatesNeutral—
19 Apr 2021NeedhamMaintainsBuy—
26 Mar 2021Morgan StanleyInitiatesEqual-Weight—
25 Mar 2021NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ERNA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ERNA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Ernexa Therapeutics, Inc. returned −95.6% against +12.4% for the S&P 500, dividends included.

ERNA vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26ERNAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ERNA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Ernexa Therapeutics, Inc. (ERNA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 75% of US stocks

Price / sales
—
Price / book
0.7×

Cheaper than 78% of US stocks

EV / EBITDA
0.1×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−320.7%

Higher than 5% of US stocks

Return on assets
−105.6%

Higher than 2% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Ernexa Therapeutics, Inc. (ERNA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Ernexa Therapeutics, Inc. has a market value of $3.2M and an enterprise value of −$1.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$12.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$8.9M.

  • Shares outstanding: 1.2M.

  • Trailing P/E: 0.0×; forward P/E: −0.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Ernexa Therapeutics, Inc. employs 5 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

ERNA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ERNAErnexa Therapeutics, Inc.$3.2M39
EOCNEocene Ltd.$3.2M13
PMCBPharmaCyte Biotech, Inc.$3.2M32
CMNDClearmind Medicine, Inc.$3.2M7
ONCOOnconetix, Inc.$3.3M15
SXTP60 Degrees Pharmaceuticals, Inc.$3.3M34
GRIGRI Bio, Inc.$3.3M33

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Ernexa Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ERNA news & analysis

Ernexa Therapeutics Highlights ERNA-101's Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment

GlobeNewsWire · 22 Oct 2026positive

Ernexa Therapeutics highlighted ERNA-101’s path toward the clinic and its cell therapy platform in a new “What This Means” segment. Leadership discussed recent FDA engagement, the technology behind ERNA-101, and the development strategy supporting planned first-in-human clinical evaluation.

Why it matters — The segment provides ERNA watchers with an update on the company’s regulatory engagement and its strategy for advancing ERNA-101 toward clinical evaluation.

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

GlobeNewsWire · 12 Oct 2026neutral

Ernexa Therapeutics announced it will participate in the Virtual Investor Closing Bell Series. The live webcast is scheduled for Thursday, October 15 at 4:00 p.m. ET and will feature CEO Sanjeev Luther, technology developer and Scientific Advisory Board member Dr. Christopher Rohde, and Chief Scientific Officer Dr. Robert Pierce.

Why it matters — ERNA watchers may note the scheduled webcast as an opportunity to hear from company leadership and scientific representatives.

Ernexa Therapeutics' ERNA-101 Selected for Flash Talk Presentation at Nature Conferences' Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center

GlobeNewsWire · 6 Oct 2026positive

Ernexa Therapeutics said preclinical data on ERNA-101 was selected for a flash talk at Nature Conferences' Next-Generation Cancer Therapeutics meeting, co-hosted by MD Anderson Cancer Center. The presentation is scheduled for October 6, 2026, in Houston, and will address the candidate's potential to activate the ovarian cancer tumor microenvironment and enhance checkpoint blockade.

Why it matters — The presentation spotlights preclinical research on ERNA-101 and its potential role in ovarian cancer treatment.

Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic

GlobeNewsWire · 1 Oct 2026positive

Ernexa Therapeutics highlighted the appointment of Dr. Robert J. Spiegel to its leadership as the company sharpens its oncology focus and advances ERNA-101 toward the clinic. The CEO discussed how the addition of the accomplished oncology drug developer strengthens Ernexa ahead of clinical development, following ERNA-101 data showing complete tumor clearance and 100% survival in combination with anti-PD-1.

Why it matters — ERNA watchers would care because the appointment of a seasoned oncology drug developer bolsters the company's leadership as it prepares to move its promising ERNA-101 candidate into clinical development.

Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND

GlobeNewsWire · 30 Sept 2026positive

Ernexa Therapeutics reported compelling ERNA-101 safety results across three IND-enabling studies, including a repeat-dose GLP toxicology study showing no drug-related adverse findings at any dose level and a single-dose assessment with no evidence of acute cytokine release. The company is advancing toward a planned Q4 2026 IND filing.

Why it matters — A clean safety profile across these pivotal IND-enabling studies removes a key development hurdle and strengthens the path toward Ernexa's planned regulatory filing for ERNA-101.

FAQ

Frequently asked questions about ERNA stock

What is the ERNA stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Ernexa Therapeutics, Inc. have a median 12-month price target of $30, with estimates ranging from $30 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ERNA stock a buy right now?

Of the 1 analysts covering Ernexa Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ernexa Therapeutics, Inc. 39 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ERNA?

As at 31 Oct 2026, Ernexa Therapeutics, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).

Will ERNA stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +1422.8% from the last close, and Ticker Nerd's factor model ranks Ernexa Therapeutics, Inc. 39 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ERNA stock forecast for 2030?

No analyst covering Ernexa Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ERNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $30 over the next 12 months.

How has ERNA stock performed over the past year?

Ernexa Therapeutics, Inc. returned -95.6% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Ernexa Therapeutics, Inc. do?

Ernexa Therapeutics Inc. is a biotechnology company focused on developing cell-based therapies for advanced cancer and autoimmune diseases.

What is the latest news on ERNA?

The most recent item we track (GlobeNewsWire, 22 Oct 2026): "Ernexa Therapeutics Highlights ERNA-101's Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment". Ernexa Therapeutics highlighted ERNA-101’s path toward the clinic and its cell therapy platform in a new “What This Means” segment. Leadership discussed recent FDA engagement, the technology behind ERNA-101, and the development strategy supporting planned first-in-human clinical evaluation.

Company

About Ernexa Therapeutics, Inc.

Ernexa Therapeutics Inc. is a biotechnology company focused on developing cell-based therapies for advanced cancer and autoimmune diseases. The company’s current programs center on engineered induced pluripotent stem cells and induced mesenchymal stem cells designed to create off-the-shelf, allogeneic treatments that can be manufactured without patient-specific cell harvesting. Its pipeline includes preclinical product candidates aimed at ovarian cancer and rheumatoid arthritis, reflecting its emphasis on therapeutic areas with high unmet medical need. Ernexa Therapeutics Inc. works at the intersection of cell engineering, immunology, and regenerative medicine, using proprietary mRNA and gene-modification technologies to direct how cells behave and deliver targeted biological effects. Headquartered in Cambridge, Massachusetts, the company operates as a clinical-stage biotechnology developer with a focused role in the evolving market for next-generation cellular medicines.

CEO Mr. Sanjeev Luther · 5 employees · United States · https://www.ernexatx.com